Cargando…

CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues

CPT-11 is a prodrug activated by carboxylesterases to the active metabolite SN-38 which is a potent inhibitor of topoisomerase I. CPT-11 is of clinical interest in the treatment of colorectal cancer. We evaluated the activities of CPT-11 converting carboxylesterase (CPT-CE) and topoisomerase I (topo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guichard, S, Terret, C, Hennebelle, I, Lochon, I, Chevreau, P, Frétigny, E, Selves, J, Chatelut, E, Bugat, R, Canal, R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362335/ https://www.ncbi.nlm.nih.gov/pubmed/10408839 http://dx.doi.org/10.1038/sj.bjc.6690364

Ejemplares similares

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
por: Delord, J P, et al.
Publicado: (2005)

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
por: Freyer, G, et al.
Publicado: (2000)

Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer Activity
por: Hsieh, Yuan-Ting, et al.
Publicado: (2015)

Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines.
por: Caliaro, M. J., et al.
Publicado: (1997)

Secreted and tumour targeted human carboxylesterase for activation of irinotecan
por: Oosterhoff, D, et al.
Publicado: (2002)

Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11
por: Oosterhoff, D, et al.
Publicado: (2005)

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
por: Vassal, G., et al.
Publicado: (1996)

Pharmacological targeting of NF-κB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells
por: Lagadec, P, et al.
Publicado: (2008)

Lycobetaine acts as a selective topoisomerase IIβ poison and inhibits the growth of human tumour cells
por: Barthelmes, H U, et al.
Publicado: (2001)

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II α gene transfer is independent of topoisomerase II β
por: Zhou, Z, et al.
Publicado: (2001)

Structural insights into catalytical capability for CPT11 hydrolysis and substrate specificity of a novel marine microbial carboxylesterase, E93
por: Li, Yang, et al.
Publicado: (2023)

Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects
por: Hardman, W E, et al.
Publicado: (1999)

Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors
por: Nelveg-Kristensen, Karl Emil, et al.
Publicado: (2016)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

No Alteration in DNA Topoisomerase I Gene Related to CPT‐11 Resistance in Human Lung Cancer
por: Ohashi, Nobuyuki, et al.
Publicado: (1996)

Carboxylesterase converts Amplex red to resorufin: Implications for mitochondrial H(2)O(2) release assays
por: Miwa, Satomi, et al.
Publicado: (2016)

DNA topoisomerase IIα and -β expression in human ovarian cancer
por: Withoff, S, et al.
Publicado: (1999)

In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6
por: Speirs, V, et al.
Publicado: (1999)

CPT and Superstring
por: Ellis, John R., et al.
Publicado: (1996)

Leptogenesis from heavy right-handed neutrinos in CPT violating backgrounds
por: Bossingham, Thomas, et al.
Publicado: (2018)

Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status
por: Bras-Gonçalves, R A, et al.
Publicado: (2000)

Small-molecule inhibitors of carboxylesterase Notum
por: Zhao, Yuguang, et al.
Publicado: (2021)

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
por: Twelves, C J, et al.
Publicado: (1999)

The signal of ill-defined CPT weakening entanglement in the [Formula: see text] system
por: Bernabéu, José, et al.
Publicado: (2017)

CP, T and CPT at CPLEAR
por: Filipcic, Andrej, et al.
Publicado: (2001)

Tests of CPT with CPLEAR
por: Adler, R, et al.
Publicado: (1996)

Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB
por: Pérez-Pertejo, Yolanda, et al.
Publicado: (2019)

The role of temperature dependent string-inspired CPT violating backgrounds in leptogenesis and the chiral magnetic effect
por: Bossingham, Thomas, et al.
Publicado: (2019)

Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma
por: Goeppert, Benjamin, et al.
Publicado: (2019)

The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics
por: Di, Li
Publicado: (2018)

Human carboxylesterases: a comprehensive review
por: Wang, Dandan, et al.
Publicado: (2018)

Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats
por: Lin, Xiaoxi B., et al.
Publicado: (2012)

Mechanism for CPT violation
por: Klinkhamer, F R
Publicado: (2001)

The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase.
por: Musk, S. R., et al.
Publicado: (1990)

Experimental tests of CPT invariance
por: Zavrtanik, D, et al.
Publicado: (2000)

Drug-induced alterations in tumour perfusion yield increases in tumour cell radiosensitivity
por: Bennewith, K L, et al.
Publicado: (2001)

Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance
por: Lage, H, et al.
Publicado: (2000)

Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases
por: Kruczynski, A, et al.
Publicado: (2000)

CPT‐11 May Provide Therapeutic Efficacy for Esophageal Squamous Cell Cancer and the Effects Correlate with the Level of DNA Topoisomerase I Protein
por: Nakajima, Yasuaki, et al.
Publicado: (2001)

The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/MAPK signaling pathway
por: Yin, Yingqiu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lq74koqqj1ogjt6nrpk491b2j2